The out-licensing agreement will result in Hyphens Pharma receiving an upfront fee and customary royalties on sales.
Hyphens Pharma International has granted the rights to commercialise its product Cerapro MED Skin Barrier Cream to Louis Widmer covering six European countries.
This is done via a licensing, supply and commercialisation agreement which spans Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.
